Lipfendra contains enlicitide, an FDA-approved oral PCSK9 inhibitor for lowering LDL in adults with hypercholesterolemia, including HeFH. It is a tablet, not an injection.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Lipfendra contains enlicitide, an FDA-approved oral PCSK9 inhibitor for lowering LDL in adults with hypercholesterolemia, including HeFH. It is a tablet, not an injection. Its LDL-lowering approval should not be presented as a separate proven cardiovascular outcomes indication.
The July 2026 label is for adults. A clinician reviews LDL, cardiovascular risk, current lipid treatment, pregnancy plans, and whether a daily tablet fits. FDA approval does not confirm a Nao service, pharmacy supply, or coverage.
The label specifies one 20 mg tablet once daily on an empty stomach in the morning. Water, black coffee, or plain tea are permitted. Swallow whole and wait at least 30 minutes before food or other drinks. It may be taken with other medicines under the label, but the clinician still reviews the full regimen.
Bring dated cholesterol panels, all lipid medicines and doses tried, adverse effects, kidney or liver results, and family history of early heart disease. Include any genetic testing, prior heart attack or stroke records, and insurance denials. Outside records can help avoid repeating information.
Review allergies, pregnancy plans, breastfeeding, kidney or liver conditions, and other medicines. Seek emergency care for breathing difficulty or a severe allergic reaction. New unexplained symptoms deserve prescriber advice rather than assuming they are expected. A cholesterol medicine does not treat an acute heart attack or stroke. Discuss pregnancy and breastfeeding. If the product cannot be obtained, arrange an LDL-care review without interrupting your existing treatment on your own.
Repeat cholesterol testing on the clinician’s schedule to assess response and adherence. Review side effects, missed doses, and refill access. Taking a cholesterol medicine does not replace laboratory monitoring or the rest of cardiovascular care. Do not stop existing medicines unless the prescriber gives a new plan.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Lipfendra contains enlicitide, an FDA-approved oral PCSK9 inhibitor for lowering LDL in adults with hypercholesterolemia, including HeFH. It is a tablet, not an injection. Its LDL-lowering approval should not be presented as a separate proven cardiovascular outcomes indication. The July 2026 label is for adults. A clinician reviews LDL, cardiovascular risk, current lipid treatment, pregnancy plans, and whether a daily tablet fits. FDA approval does not confirm a Nao service, pharmacy supply, or coverage.
No. Lipfendra is oral enlicitide, a tablet taken once daily under its fasting instructions. It differs from injectable PCSK9 treatments.
Lipfendra has a US-approved label for LDL reduction, but its availability through your chosen Nao clinic needs direct confirmation. Ask whether the clinician evaluates and prescribes it, which pharmacy can fill it and what authorization or tests are needed. Keep the existing cholesterol plan until the clinician sets any change; a product approval does not establish a clinic treatment start.
FDA approval applies to the medicine and its labeled uses. A clinic can still need to arrange prescribing, dispensing, coverage and follow-up before offering a service. Ask about prescription arrangements, pharmacy availability and cholesterol-care options. Continue existing treatment until your clinician sets a change.
The label specifies one 20 mg tablet once daily on an empty stomach in the morning. Water, black coffee, or plain tea are permitted. Swallow whole and wait at least 30 minutes before food or other drinks. It may be taken with other medicines under the label, but the clinician still reviews the full regimen.
Lipfendra’s current indication is LDL reduction in adults with hypercholesterolemia, including HeFH. The label’s discussion of cardiovascular outcomes from other treatments is not a separate Lipfendra cardiovascular outcomes indication.
Arrange a review of your current condition and prescribed treatment without waiting for a new product. Bring dated cholesterol panels, all lipid medicines and doses tried, adverse effects, kidney or liver results, and family history of early heart disease. Include any genetic testing, prior heart attack or stroke records, and insurance denials. Outside records can help avoid repeating information. Confirm the available service and clinician. Do not interrupt existing medicine yourself.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
